Medicare has different standards than the FDA. That’s how it should be; Listen: Vertex’s polarizing data, Aduhelm’s adieu, & an FDA icon

Taking stock of the drug industry, from the lab to the medicine chest

February 2, 2024 Check out STAT+

Sponsored By

By Ed Silverman Pharmalot Columnist, Senior Writer

Adobe Opinion: Medicare has different standards than the FDA. That's how it should be Lobbyists appear to have convinced many policymakers and the public to demand that Medicare should pay for all drugs that the FDA approves. By Diana Zuckerman Listen: Vertex's polarizing data, Aduhelm's adieu, & an FDA icon This episode, we explain the debate over Vertex's novel pain drug, whose success in clinical trials comes with a sizable caveat. By Damian Garde and Allison DeAngelis and Adam Feuerstein STAT+ | Up and down the ladder: The latest comings and goings From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry. By Ed Silverman Adobe Opinion: Can Arena Bioworks upend the traditional scientific research model in the U.S.? Arena Bioworks' plan to build a biomedical research institute outside of the university is promising — but there is much to be learned. By Paula Stephan

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Pharmalot? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2024, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser